| Literature DB >> 32497317 |
V D'Ovidio1, C Lucidi1, G Bruno1, L Miglioresi1, D Lisi1, M E Bazuro1.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32497317 PMCID: PMC7301017 DOI: 10.1111/jgh.15132
Source DB: PubMed Journal: J Gastroenterol Hepatol ISSN: 0815-9319 Impact factor: 4.369
Focus on upper gastrointestinal bleeding
| Lockdown group ( | Control group ( | ||
|---|---|---|---|
| NSAID abuse, | 3 (23) | 5 (21) | 0.7700 |
| Antithrombotic treatments, | 4 (30) | 6 (25) | 0.7 |
| Onset evident bleeding (mean days) | 6.5 ± 1.6 (range 1–10) | 1.7 ± 0.6 (range 1–3) | 0.0001 |
| Hemoglobin at admission (g/dL) | 6.5 ± 2 (range 3–12) | 9.9 ± 2.5 (range 5–14) | 0.0010 |
| Need of Blood transfusion, | 13 (77) | 23 (17) | 0.0010 |
| Severity of bleeding endoscopic stigmata (Forrest classification) | Total ( | Total ( | 0.04 |
| III Clean‐based ulcer | 3 (30) | 7 (64) | |
| IIc Flat pigmented hematinic | 2 (20) | 0 | |
| IIb Adherent clot | 0 | 3 (27) | |
| IIa Non‐bleeding visible vessel | 3 (30) | 0 | |
| Ib Active oozing | 2 (20) | 1 (9) | |
| Ia Active spurter | 0 | 0 | |
| Endoscopic treatment | 5 (50) | 4 (36) | 0.52 |
|
| 6 (46) | 7 (29) | 0.3 |